BIOLIFE SOLUTIONS INC (BLFS)
Health Care · Biopreservation and cell processing for cell and gene therapy · NASDAQ
BioLife Solutions develops biopreservation media and cell processing products designed to improve quality and reduce risk in cell and gene therapy manufacturing and distribution.
What BIOLIFE SOLUTIONS INC does
BioLife Solutions is a life sciences company that develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry. The company's portfolio focuses on biopreservation media and cell processing products that help customers maintain the health and function of biologic material during sourcing, manufacturing, and distribution. The company leverages in-house expertise in cryobiology and broader CGT workflows to support multiple steps in biologic material manufacturing and delivery. Recent strategic moves include the acquisition of PanTHERA's Ice Recrystallization Inhibitor technology and the divestiture of non-core businesses (SAVSU, CBS, SciSafe, Global Cooling) to focus on core biopreservation capabilities.
Themes: Cell and gene therapy (CGT), Biopreservation, Biologic manufacturing, Cryopreservation technology, Regenerative medicine supply chain
Fundamentals
- Price$37.10 as of 2026-08-21 close
- Market cap$1.8B as of 2026-08-21
- 1-year return+47.9% 2025-08-21 close $25.08 → 2026-08-21 close $37.10
- P/E29.72 as of 2026-08-24
- Net margin+56.4% as of 2026-08-24
- Gross margin+63.9% as of 2026-08-24
- ROE+15.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+34.4% as of 2026-08-24
- Revenue CAGR (3y)+30.9% SEC XBRL
- Beta1.85 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How BLFS compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How BIOLIFE SOLUTIONS INC looks technically
BIOLIFE SOLUTIONS INC (BLFS) is trading 48.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 36 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 67, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is 2.6% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 48.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +48.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $30.30 | $30.30 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $24.93 | $24.93 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 30. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 36 trading days ago — a "golden cross", a bullish long-term signal | 36 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 67, with buyers in control | 67.3 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70) | 78.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($31.46 to $38.10) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 84.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 23 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $38.10 | $38.10 |
|---|---|---|
| From the 52-week high | it is 2.6% below its 52-week high (its highest price of the past year) | -2.6% |
| Above the 52-week low | it is 107.7% above its 52-week low (its lowest price of the past year) | +107.7% |
| Below the 52-week high | it is 2.6% below its highest point of the past year | 2.6% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $60.67 (set on 2021-09-01) | $60.67 |
| Given back of the 52-week move | over the past year its closes ranged ($18.15 to $37.10), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $24.78 to $25.39. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 38.8% below its all-time high | -38.9% |
| Nearest price level | it is trading 19.9% above a support level at $29.72 — a price it turned at three times since 2025-01-30, most recently on 2026-06-29. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -19.9% |
| All-time low | its lowest closing price on record is $0.1408 (set on 2008-10-10) | $0.1408 |
| Above the all-time low | it is 26241.0% above its all-time low | +26,241% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.17 between its high and its low — about 3.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.17 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $29.96 and $37.93 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $29.96 – $33.95 – $37.93 |
| Typical daily range (% of price) | its price moves about 3.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.2% |
| Stretch from the 200-day average | it is trading 10.4 daily ranges above its 200-day average price (48.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.62× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.5% since the prior reading | +0.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.22 toward sell |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 2.3% above the previous close 18 sessions ago and has not traded back through the level it left behind at 29.79 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.3% |
| Gap filled | a 2.5% gap down opened on 2026-08-10 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +6.18% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 24.8 percentage points (the stock gained 27.1% while the market gained 2.3%) | +24.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 46.9 percentage points (the stock gained 50.0% while the market gained 3.1%) | +46.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 49.6 percentage points (the stock gained 60.7% while the market gained 11.1%) | +49.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 27.4 percentage points (the stock gained 47.9% while the market gained 20.5%) | +27.4% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 32% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 8.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +32.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 39% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $26.62 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +39.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $35.52 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +4.4% |
Price levels it has turned at before
BLFS last closed at $37.10 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $29.72 | Support | 19.9% below the last close | turned there three times · 2025-01-30 to 2026-06-29 |
| $28.95 | Support | 22.0% below the last close | turned there three times · 2024-11-13 to 2025-10-16 |
| $28.43 | Support | 23.4% below the last close | turned there twice · 2024-12-20 to 2025-01-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $30.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $30.05 and $31.67 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.78 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$31.29 range $31.00 – $33.00; median $31.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BLFS
- Consensus EPS estimate$0.07 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on cell and gene therapy market adoption and regulatory approval timelines, which are inherently uncertain and subject to long development cycles","Integration risk and potential impairment of goodwill ($208.6M) and intangible assets related to acquisitions such as PanTHERA","Company remains unprofitable with -2.97% net margin; recent profitability is dependent on interest income and other gains, not core operations"]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 3 sells ($28M) — 1 selling insider
Most recent open-market transaction: 2026-05-21. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BLFS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding BLFS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,600,393
- Reported value $183,175,493
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BLFS had 4,544,348 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BLFS had 9.29% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.06 days to cover at the same settlement.
- Reported short interest (shares) 4,544,348
- Short interest (% of shares outstanding) 9.29%
- Prior settlement (shares) 2,856,425
- Reported change 59.09%
- Days to cover (reported) 2.06
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Lonza Group (LZAGY)
- Danaher (DHR)
- Merck KGaA (MRK.DE)
- Sartorius AG (SRT.DE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BLFS vs…
BLFS shows up in…
Frequently asked questions
What does BIOLIFE SOLUTIONS INC (BLFS) do?
BioLife Solutions is a life sciences company that develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry. The company's portfolio focuses on biopreservation media and cell processing products that help customers maintain the health and function of biologic material during sourcing, manufacturing, and distribution.
What sector is BIOLIFE SOLUTIONS INC (BLFS) in?
BIOLIFE SOLUTIONS INC (BLFS) is classified in the Health Care sector. Its industry is Biopreservation and cell processing for cell and gene therapy. It trades on NASDAQ.
Who are BIOLIFE SOLUTIONS INC's (BLFS) competitors?
Notable peers of BIOLIFE SOLUTIONS INC (BLFS) include Thermo Fisher Scientific, Lonza Group, Danaher, Merck KGaA and Sartorius AG. This peer set is informational only — not financial advice.
Is BIOLIFE SOLUTIONS INC (BLFS) overbought or oversold right now?
BIOLIFE SOLUTIONS INC (BLFS) is currently in overbought territory (its 14-day RSI is 78, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BLFS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.